RecruitingPhase 2NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Fausto Castagnetti"Seragnoli" Institute of Hematology Bologna (Italy)
- Intervention
- Asciminib(drug)
- Enrollment
- 160 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (11)
- Hospital del Mar (Barcelona), Barcelona, Spain
- Hospital Universitario Basurto, Bilbao, Spain
- Institut Català d'Oncologia Girona, Girona, Spain
- Hospital Virgen de las Nieves, Granada, Spain
- Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Hospital Gral U. Gregorio Marañón, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Universitario La Paz, Madrid, Spain
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
- Hospital Universitario La Fe Valencia, Valencia, Spain
Collaborators
Grupo Español de Leucemia Mieloide Crónica
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06409936 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics
- RECRUITINGNCT06297161A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).Pfizer